Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: A model-based analysis.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
01
08
2020
accepted:
03
03
2021
revised:
06
04
2021
pubmed:
26
3
2021
medline:
30
7
2021
entrez:
25
3
2021
Statut:
epublish
Résumé
Emergence of resistance to artemisinin and partner drugs in the Greater Mekong Subregion has made elimination of malaria from this region a global priority; it also complicates its achievement. Novel drug strategies such as triple artemisinin combination therapies (ACTs) and chemoprophylaxis have been proposed to help limit resistance and accelerate elimination. The objective of this study was to better understand the potential impacts of triple ACTs and chemoprophylaxis, using a mathematical model parameterized using data from Cambodia. We used a simple compartmental model to predict trends in malaria incidence and resistance in Cambodia from 2020-2025 assuming no changes in transmission since 2018. We assessed three scenarios: a status quo scenario with artesunate-mefloquine (ASMQ) as treatment; a triple ACT scenario with dihydroartemisinin-piperaquine (DP) plus mefloquine (MQ) as treatment; and a chemoprophylaxis scenario with ASMQ as treatment plus DP as chemoprophylaxis. We predicted MQ resistance to increase under the status quo scenario. Triple ACT treatment reversed the spread of MQ resistance, but had no impact on overall malaria incidence. Joint MQ-PPQ resistance declined under the status quo scenario for the baseline parameter set and most sensitivity analyses. Compared to the status quo, triple ACT treatment limited spread of MQ resistance but also slowed declines in PPQ resistance in some sensitivity analyses. The chemoprophylaxis scenario decreased malaria incidence, but increased the spread of strains resistant to both MQ and PPQ; both effects began to reverse after the intervention was removed. We conclude that triple ACTs may limit spread of MQ resistance in the Cambodia, but would have limited impact on malaria incidence and might slow declines in PPQ resistance. Chemoprophylaxis could have greater impact on incidence but also carries higher risks of resistance. Aggressive strategies to limit transmission the GMS are needed to achieve elimination goals, but any intervention should be accompanied by monitoring for drug resistance.
Identifiants
pubmed: 33764971
doi: 10.1371/journal.pcbi.1008850
pii: PCOMPBIOL-D-20-01377
pmc: PMC8023453
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008850Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Trends Parasitol. 2019 Jun;35(6):388-398
pubmed: 31076353
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Antimicrob Agents Chemother. 2009 Apr;53(4):1509-15
pubmed: 19164150
Lancet. 2014 Feb 22;383(9918):723-35
pubmed: 23953767
PLoS One. 2012;7(5):e37166
pubmed: 22662135
N Engl J Med. 2019 May 30;380(22):2087-2089
pubmed: 31018065
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):739-49
pubmed: 10365399
Malar J. 2014 Nov 23;13:452
pubmed: 25418416
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14216-21
pubmed: 18780786
Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):39-50
pubmed: 25897063
Malar J. 2020 Apr 15;19(1):151
pubmed: 32293452
Malar J. 2018 Aug 2;17(1):279
pubmed: 30071877
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30150462
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12106-11
pubmed: 9342370
Lancet Infect Dis. 2017 Feb;17(2):184-193
pubmed: 27865890
Biometrics. 2010 Dec;66(4):1162-73
pubmed: 20222935
Sci Rep. 2019 Dec 13;9(1):19060
pubmed: 31836757
Malar J. 2016 Jan 06;15:10
pubmed: 26739092
Nat Med. 2004 Oct;10(10):1117-21
pubmed: 15378056
Lancet Glob Health. 2015 Dec;3(12):e758-66
pubmed: 26545449
Malar J. 2009 Feb 20;8:31
pubmed: 19228438
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
PLoS One. 2008 Mar 12;3(3):e1767
pubmed: 18335042
Lancet Infect Dis. 2017 Dec;17(12):1233
pubmed: 29173875
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 5;370(1670):20140306
pubmed: 25918446